Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Note
Inhibitory Effects of Lysophospholipids on Survival and Interleukin-8 Secretion of HT-29, a Human Colon Cancer-Derived Epithelial Cell
Yuya Ohtsuki, Erena Nakamura, Moe Asakami, Rena Morikawa, Akira Tokumura
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML
Supplementary material

2025 Volume 48 Issue 2 Pages 119-125

Details
Abstract

Lysophpsphospholipids (LPLs) are lipid mediators involved in various physiological functions. In daily diets, people consume large amounts of various lipids, including LPLs. Exogenous dietary LPLs initially affect epithelial cells and, finally, the entire colon and may be linked to the onset and prevention of colonic diseases, including inflammatory bowel disease. However, the effects of exogenous LPLs on epithelial cells remain poorly understood. In this study, we used HT-29, a human colon cancer-derived epithelial cell, to evaluate the effects of LPLs on epithelial cells under normal and inflammatory states. In the absence of lipopolysaccharide (LPS), several LPLs decreased interleukin-8 (IL-8) secretion from HT-29 cells in the following order of potency based on the reduction ratio at the highest concentration: lysophosphatidylglycerol > lysophosphatidylcholine > lysophosphatidyletanolamine > lysophosphatidylserine. In the presence of LPS, only lysophosphatidylinositol (LPI) decreased the IL-8 secretion induced by LPS. Focusing on the G protein-coupled receptors (GPCRs) that LPI acts on, PSN375963 and AS1269574, GPR119 agonists, decreased the IL-8 secretion induced by LPS. It is speculated that IL-8 secretion was reduced by LPI via GPR119 signaling under non-inflammatory conditions. Although the detailed mechanism remains to be elucidated, the findings that LPLs, except for LPI, have inhibitory effects and that LPI has an inhibitory/anti-inflammatory effect on IL-8 secretion will help to elucidate the mechanism on the onset of colonic diseases and the planning of treatment methods in the future.

Fullsize Image
Content from these authors
© 2025 Author(s).
Published by The Pharmaceutical Society of Japan

This article is licensed under a Creative Commons [Attribution-NonCommercial 4.0 International] license.
https://creativecommons.org/licenses/by-nc/4.0/
Previous article Next article
feedback
Top